The system was the first to allow people with diabetes to monitor blood glucose without fingersticks. Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...
Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...
The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval fromHealth Canada for adults and children (4 and older) with diabetes. With new ...
twiist™ AID system powered by Tidepool expected to launch Q2 2025 in the U.S. with Abbott's FreeStyle Libre® 3 Plus sensor MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a ...
ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback